PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback